eligibility_summary
Adults (≥18) with MM per IMWG, measurable at diagnosis, who completed 12–13 cycles of Dara‑Rd and will continue it, lenalidomide dose ≥5 mg and prior dexamethasone reduction/stop allowed, ≥partial response without biochemical progression, ANC ≥1.0×10^9/L, platelets ≥75×10^9/L, able to consent. Exclude non‑secretory MM, plasmacytoma‑only or urine M‑protein–only measurable disease at diagnosis, stopped dara/len, inability to continue, or poor compliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06187441 (HOVON174MM/FABULOUS): Phase 3, open-label RCT in newly diagnosed multiple myeloma comparing continuous Dara-Rd versus a treatment‑free interval after 12 cycles, with Dara‑Rd resumed at biochemical progression. Drugs/mechanisms (types): • Daratumumab (monoclonal antibody): targets CD38 on plasma cells, mediates ADCC, CDC, ADCP, and apoptosis, depletes CD38+ immunosuppressive cells (Tregs, Bregs, MDSCs), enhancing T/NK responses. • Lenalidomide (IMiD): binds cereblon (CRBN) E3 ligase, causing IKZF1/3 degradation, boosts T/NK activation, anti-myeloma and anti-angiogenic effects. • Dexamethasone (glucocorticoid): GR-mediated apoptosis of lymphoid/plasma cells, anti-inflammatory. Targeted cells/pathways: CD38+ malignant plasma cells, immune effector pathways (NK/T-cell cytotoxicity, complement), CRBN–IKZF1/3 axis, glucocorticoid receptor signaling, tumor-supportive marrow microenvironment.